Preoperative blood transfusions for sickle cell disease

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 4, 2016, Pages

  Estcourt, Lise J ^a   Fortin, Patricia M ^a   Trivella, Marialena ^b   Hopewell, Sally ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN S;

ACUTE CHEST SYNDROME; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; ELECTIVE SURGERY; EMERGENCY SURGERY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN SC DISEASE; HUMAN; KIDNEY DISEASE; LENGTH OF STAY; NEUROLOGICAL COMPLICATION; OUTCOME ASSESSMENT; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PREOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; SURGICAL INFECTION; SYSTEMATIC REVIEW; ADVERSE EFFECTS; ANEMIA, SICKLE CELL; BLOOD; META ANALYSIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA, SICKLE CELL; BLOOD TRANSFUSION; HEMOGLOBIN, SICKLE; HUMANS; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84962764647     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003149.pub3     Document Type: Review

References (67)

1. Al-Jaouni S, Al-Muhayawi S, Qari M, Nawas MA, Abdel-Razeq H. The safety of avoiding transfusion preoperatively in patients with sickle cell hemoglobinopathies [abstract]. Blood 2002;100(11 Pt 2 of 2):21b.
2. Al-Jaouni SK, Al-Muhayawi SM, Qari MH, Nawas MA, Al-Mazrooa A. Randomized clinical trial to evaluate the safety of avoiding pre-operative transfusion in sickle cell anemia. Bahrain Medical Bulletin 2006;28(4):164-7.
3. Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet 2013;381:930-8.
4. Howard J, Malfroy M, Llewelyn C, Chow L, Rees D, Walker I, et al. Pre-operative transfusion reduces serious adverse events in patients with sickle cell disease (SCD): Results from the transfusion alternatives preoperatively in sickle cell disease (TAPS) randomised controlled multicentre clinical trial [abstract]. Blood 2011;118(21):Abstract no: 9.
5. NCT00512577 Transfusion alternatives pre-operatively in sickle cell disease (TAPS). https://clinicaltrials.gov/show/NCT00512577 (accessed 23 July 2015).
6. Spackman E, Sculpher M, Howard J, Malfroy M, Llewelyn C, Choo L, et al. Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial. European Journal of Haematology 2014;92(3):249-55. [CENTRAL: 986585; CRS: 5500135000000956; PUBMED: 24329965]
7. Haberkern CM, Neumayr L, Earles AN, Robertson S, Black D, Orringer EP, et al. Cholecystectomy in sickle cell anemia (SCA) patients: report of 364 patients from the preoperative transfusion study [abstract]. Blood 1995;86(10 Suppl 1):142a.
8. Haberkern CM, Neumayr L, Earles AN, Robertson S, Black D, Orringer EP, et al. Cholecystectomy in sickle cell anemia patients: report of 364 patients from the Preoperative Transfusion Study [abstract]. Proceedings of the 21st Annual Meeting of the National Sickle Cell Disease Program. 1996:45.
9. Haberkern CM, Neumayr LD, Orringer EP, Earles AN, Robertson SM, Black D, et al. Cholecystectomy in sickle cell anemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Preoperative Transfusion in Sickle Cell Disease Study Group. Blood 1997;89(5):1533-42.
10. Neumayr L, Koshy M, Haberkern C, Earles AN, Bellevue R, Hassell K, et al. Surgery in patients with hemoglobin SC disease. Preoperative Transfusion in Sickle Cell Disease Study Group. American Journal of Hematology 1998;57(2):101-8.
11. Orringer EP, Olivieri NF, Neumayr L, Haberkern C, Vichinsky EP. Is preoperative transfusion always necessary in sickle cell anemia (SCA)? [abstract]. Blood 1995;86 Suppl:300a.
12. Preoperative Transfusion Study Group. Preliminary report on preoperative transfusion study in sickle cell disease [abstract]. Proceedings of the 14th Annual Meeting of the National Sickle Cell Disease Program. 1989:63.
13. Vichinsky EP, Haberkern CM, Neumayr L, Earles AN, Black D, Koshy M, et al. A comparison of conservative and aggressive transfusion regimes in the perioperative management of sickle cell disease. New England Journal of Medicine 1995;333(4):206-13.
14. Vichinsky EP, Neumayr LD, Haberkern C, Earles AN, Eckman J, Koshy M, et al. The perioperative complication rate of orthopedic surgery in sickle cell disease: report of the National Sickle Cell Surgery Study Group. American Journal of Hematology 1999;62(3):129-38.
15. Vichinsky EP, The NPTSG. High rates of complications in sickle cell anemia (SCA) patients undergoing orthopedic surgery [abstract]. Proceedings of the 22nd Annual Meeting of the National Sickle Cell Disease Program. 1997:182.
16. Waldron P, Pegelow C, Neumayr L, Haberkern C, Earles A, Wesman R, et al. ENT surgery in sickle cell disease: perioperative morbidity [abstract]. Proceedings of the 22nd Annual Meeting of the National Sickle Cell Disease Program. 1997:124.
17. Waldron P, Pegelow C, Neumayr L, Haberkern C, Earles A, Wesman R, et al. Tonsillectomy, adenoidectomy and myringotomy in sickle cell disease: perioperative morbidity. Journal of Pediatric Hematology/Oncology 1999;21(2):129-35.
18. Alotaibi GS, Alsaleh K, Bolster L, McMurtry MS, Wu C. Preoperative transfusion in patients with sickle cell disease to prevent perioperative complications: a systematic review and meta-analysis. Hematology (Amsterdam, Netherlands) 2014;19:463-71.
19. Aziz AM, AW Meshikhes. Blood transfusion in patients with sickle cell disease requiring laparoscopic cholecystectomy. Journal of the Society of Laparoendoscopic Surgeons 2011;15:480-5.
20. Daigavane MM, Jena RK, Kar TJ. Perinatal outcome in sickle cell anemia: a prospective study from India. Hemoglobin 2013;37:507-15.
21. Debaun MR, Field JJ. Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. Hematology 2007;2007:482-8.
22. El-Shafei AM, Kaur Dhaliwal J, Kaur Sandhu A, Rashid Al-Sharqi M. Indications for blood transfusion in pregnancy with sickle cell disease. Australian & New Zealand Journal of Obstetrics & Gynaecology 1995;35:405-8.
23. Geoghegan J, Middleton L, Moore P, Subseson G, Khan K, Daniels J. Routine cell salvage during elective caesarean section: A pilot randomised trial. International Journal of Obstetric Anesthesia 2015;24:86-7.
24. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study. New England Journal of Medicine 1988;319:1447-52.
25. Orringer EP, Olivieri NF, Neumayr L, Haberkern C, Bichinsky EP. Is preoperative transfusion always necessary in sickle cell anemia (SCA)? [abstract]. Blood 1995;86:300a.
26. Styles LA, Abboud M, Larkin S, Lo M, Kuypers FA. Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2. British Journal of Haematology 2007;136:343-4.
27. Wali YA, al Okbi H, al Abri R. A comparison of two transfusion regimens in the perioperative management of children with sickle cell disease undergoing adenotonsillectomy. Pediatric Hematology and Oncology 2003;20(1):7-13.
28. Adam S, Jonassaint J, Kruger H, Kail M, Orringer E P, Eckman J R, et al. Surgical and obstetric outcomes in adults with sickle cell disease. American Journal of Medicine 2008;121:916-21.
29. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011;118(1):19-27.
30. Ansong D, Osei Akoto A, Ocloo D, Ohene-Frempong K. Sickle cell disease: management options and challenges in developing countries. Mediterr J Hematol Infect Dis 2013;5(1):e2013062.
31. Buck J, Casbard A, Llewelyn C, Johnson T, Davies S, Williamson L. Preoperative transfusion in sickle cell disease: a survey of practice in England.[Erratum appears in Eur J Haematol. 2005 Sep;75(3):271]. European Journal of Haematology 2005;75:14-21.
32. Chakravorty S, Williams TN. Sickle cell disease: a neglected chronic disease of increasing global health importance. Archives of Disease in Childhood 2015;100(1):48-53.
33. Chou ST. Transfusion therapy for sickle cell disease: a balancing act. Hematology 2013;2013:439-46.
34. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Whesthoff CM. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood 2013;122(6):1062-71.
35. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
36. Frenette PS, Atweh GF. Sickle cell disease: old discoveries, new concepts, and future promise. The Journal of Clinical Investigation 2007;117(4):850-8.
37. Gravitz L, Pincock S. Sickle-cell disease. Nature 2014;515:S1.
38. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, PhD, Williams TN. Sickle cell disease in Africa. A neglected cause of early childhood mortality. American Journal of Preventive Medicine 2011;41(6S4):S398-S405.
39. Haberkern CM, Neumayr LD, Orringer EP, Earles AN, Robertson SM, Black D, et al. Cholecystectomy in sickle cell anaemia patients: perioperative outcome of 364 cases from the National Preoperative Transfusion Study. Blood 1997;89(5):1533-42.
40. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
41. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
42. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. Hyder O, Yaster M, Bateman BT, Firth PG. Surgical procedures and outcomes among children with sickle cell disease. Anesthesia & Analgesia 2013;117:1192-6.
44. Kanter J, Kruse-Jarres R. Management of sickle cell disease from childhood through adulthood. Blood Reviews 2013;27:279-87.
45. Kato GJ, McGowan V, Machado RF, Little JA, Taylor J, Morris CR, et al. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood 2006;107(6):2279-85.
46. Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated with sickle cell pulmonary hypertension. American Journal of Hematology 2006;81:503-10.
47. NICE National Institute for Health and Care Excellence. Sickle cell disease. http://cks.nice.org.uk/sickle-cell-disease#!backgroundsub:3. London: NICE, (accessed 22 March 20167), issue http://cks.nice.org.uk/sickle-cell-disease#!backgroundsub:3.
48. Ould Amar K, Rouvillain JL, Loko G. Perioperative transfusion management in patients with sickle cell anaemia undergoing a total hip arthroplasty. Is there a role of red-cell exchange transfusion? A retrospective study in the CHU of Fort-de-France Martinique. Transfusion Clinique et Biologique 2013;20:30-4.
49. Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet 2012;381:142-51.
50. Pleasants S. Epidemiology: a moving target. Nature 2014;515:S2-3.
51. Porter J, Garbowski M. Consequences and management of iron overload in sickle cell disease. ASH Education Program Book 2013;1:447-56.
52. Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet 2010;376:2018-31.
53. The Nordic Cochrane Centre. Review Manager (RevMan). Version 5.3. Copenhagen: The Cochrane Collaboration, 2014.
54. Rumaney MB, Ngo Bitoungui VJ, Vorster AA, Ramesar R, Kengne AP, Ngogang J, et al. The co-inheritance of alpha-thalassemia and sickle cell anemia Is associated with better hematological indices and lower consultations rate in Cameroonian patients and could improve their survival. PLoS ONE 2014;9(6):e100516.
55. Scheunemann LP, Ataga KI. Delayed hemolytic transfusion reaction in sickle cell disease. The American Journal of the Medical Sciences 2010;339(3):266-9.
56. Schmalzer EA, Lee JO, Brown AK, Usami S, Chien S. Viscosity of mixtures of sickle and normal red cells at varying hematocrit levels. Implications for transfusion. Transfusion 1987;27(3):228-33.
57. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
58. Sparkenbaugh E, Pawlinski R. Interplay between coagulation and vascular inflammation in sickle cell disease. British Journal of Haematology 2013;162(1):3-14.
59. Stanley AC, Christian JM. Sickle cell disease and perioperative considerations: review and retrospective report. Journal of Oral and Maxillofacial Surgery 2013;71:1027-33.
60. Steinberg MH, Sebastiani P. Genetic modifiers of sickle cell disease. American Journal of Hematology 2012;87:795-803.
61. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
62. Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Systematic Reviews 2014;3:54.
63. Ubesie A, Emodi I, Ikefuna A, Ilechukwu G, Ilechukwu G. Prevalence of Human Immunodeficiency Virus Transmission among Transfused Children with Sickle Cell Anemia in Enugu Nigeria. Annals of Medical and Health Sciences Research 2012;2(2):109-113.
64. Waldron P, Pegelow C, Neumayr L, Haberkern C, Earles A, Wesman R, et al. Tonsillectomy, adenoidectomy and myringotomy in sickle cell disease: perioperative morbidity. Journal of Pediatric Hematology/Oncology 1999;21(2):129-35.
65. Yawn BP, Buchanan GR, Afenyi-Annan AN, Ballas SK, Hassell KL, James AH, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA 2014;312(10):1033-48.
66. Hirst C, Williamson L. Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD003149]
67. Hirst C, Williamson L. Preoperative blood transfusions for sickle cell disease. Cochrane Database of Systematic Reviews 2012, Issue 1. [DOI: 10.1002/14651858.CD003149.pub2]